Interpace Biosciences
Interpace Biosciences, Inc. (OTC: IDXG) is a molecular diagnostics company providing diagnostic testing services and molecular pathology solutions that help clinicians make more informed decisions in the diagnosis, staging, and management of thyroid cancer, gastrointestinal cancers, and other malignancies where molecular diagnostic information can guide treatment decisions and improve patient outcomes. According to its website at interpace.com, the company's laboratory performs specialized molecular diagnostic tests on tissue and cytology samples, providing oncologists, endocrinologists, gastroenterologists, and other clinicians with actionable molecular information about patients' tumors that complements conventional pathology analysis and imaging in cancer diagnosis and management. Interpace's clinical diagnostic testing services represent the primary revenue-generating activity of the business, serving healthcare providers seeking molecular diagnostic insights to guide cancer treatment planning.
Interpace Biosciences' diagnostic test portfolio, described at interpace.com, includes ThyGeNEXT — a molecular test for thyroid nodule evaluation that uses next-generation sequencing to identify genetic mutations and fusions associated with thyroid malignancy, helping guide decisions about whether to surgically remove thyroid nodules diagnosed as indeterminate by conventional cytology; ThyraMIR — an expression profiling test that complements ThyGeNEXT in thyroid nodule assessment; PancraGEN — a molecular test for pancreatic cyst evaluation; BarreGEN — a test for esophageal cancer risk assessment in patients with Barrett's esophagus; and other molecular diagnostic products addressing cancer detection and risk stratification needs across gastrointestinal and endocrine oncology. These tests provide clinicians with molecular information that enhances diagnostic confidence and may enable more appropriate surgical decision-making for cancer patients.
Interpace Biosciences' commercial operations focus on building utilization of its molecular diagnostic test portfolio among oncology and specialty physician practices, hospital systems, and academic medical centers that manage significant cancer patient populations. According to interpace.com, the company's commercial strategy involves direct sales to high-volume thyroid, gastrointestinal, and cancer specialty physicians and institutions where Interpace's molecular tests can demonstrate clinical utility in improving diagnostic accuracy and patient management decisions. Interpace's combination of thyroid cancer molecular diagnostics leadership, expanding gastrointestinal cancer diagnostic portfolio, clinical evidence base for its tests, and specialty physician commercial focus positions it as a focused participant in the growing molecular diagnostics market for cancer detection and characterization.